These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

815 related items for PubMed ID: 31227464

  • 1. Positron Emission Tomography/Computed Tomography with Gallium-68-labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model.
    Alvim R, Nagar K, Das S, Lebdai S, Wong N, Somma A, Hughes C, Thomas J, Monette S, Scherz A, Kim K, Grimm J, Coleman JA.
    Eur Urol Focus; 2021 Mar; 7(2):472-478. PubMed ID: 31227464
    [Abstract] [Full Text] [Related]

  • 2. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [Abstract] [Full Text] [Related]

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Sep; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of Gallium-68 prostate-specific membrane antigen, positron emission tomography/computed tomography (GA-68 PSMA PET/CT) in recurrent prostate cancer: a retrospective review of initial clinical experience at Tygerberg Hospital.
    Sangiwa BA, Burger C, Ellmann A.
    Pan Afr Med J; 2024 Sep; 48():30. PubMed ID: 39220559
    [Abstract] [Full Text] [Related]

  • 5. 68Ga-PSMA PET/CT in Patients with Rising Prostatic-Specific Antigen After Definitive Treatment of Prostate Cancer: Detection Efficacy and Diagnostic accuracy.
    Hamed MAG, Basha MAA, Ahmed H, Obaya AA, Afifi AHM, Abdelbary EH.
    Acad Radiol; 2019 Apr; 26(4):450-460. PubMed ID: 29935970
    [Abstract] [Full Text] [Related]

  • 6. Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach.
    Albisinni S, Artigas C, Aoun F, Biaou I, Grosman J, Gil T, Hawaux E, Limani K, Otte FX, Peltier A, Sideris S, Sirtaine N, Flamen P, van Velthoven R.
    BJU Int; 2017 Aug; 120(2):197-203. PubMed ID: 27981732
    [Abstract] [Full Text] [Related]

  • 7. Gallium-68-prostate-specific membrane antigen (68 Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancer.
    van Leeuwen PJ, Donswijk M, Nandurkar R, Stricker P, Ho B, Heijmink S, Wit EMK, Tillier C, van Muilenkom E, Nguyen Q, van der Poel HG, Emmett L.
    BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
    [Abstract] [Full Text] [Related]

  • 8. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer.
    Meijer D, Eppinga WSC, Mohede RM, Vanneste BGL, Meijnen P, Meijer OWM, Daniels LA, van den Bergh RCN, Lont AP, Ettema RH, Oudshoorn FHK, van Leeuwen PJ, van der Poel HG, Donswijk ML, Oprea-Lager DE, Schaake EE, Vis AN.
    Eur Urol Oncol; 2022 Apr; 5(2):146-152. PubMed ID: 35074282
    [Abstract] [Full Text] [Related]

  • 9. [68Ga]Ga-PSMA-11 PET-CT: Local preliminary experience in prostate cancer biochemical recurrence patients.
    Carvalho J, Nunes P, Da Silva ET, Silva R, Lima J, Quaresma V, Figueiredo A.
    Arch Ital Urol Androl; 2021 Mar 18; 93(1):21-25. PubMed ID: 33754603
    [Abstract] [Full Text] [Related]

  • 10. The use of 68Ga-PET/CT PSMA to determine patterns of disease for biochemically recurrent prostate cancer following primary radiotherapy.
    Raveenthiran S, Yaxley J, Gianduzzo T, Kua B, McEwan L, Wong D, Tsang G, MacKean J.
    Prostate Cancer Prostatic Dis; 2019 Sep 18; 22(3):385-390. PubMed ID: 31363165
    [Abstract] [Full Text] [Related]

  • 11. A Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging.
    McCarthy M, Francis R, Tang C, Watts J, Campbell A.
    Int J Radiat Oncol Biol Phys; 2019 Jul 15; 104(4):801-808. PubMed ID: 30890448
    [Abstract] [Full Text] [Related]

  • 12. Risk of metastatic disease on 68 gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer.
    Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley WJ, Coughlin G, Yaxley AJ, Gianduzzo T, Kua B, McEwan L, Wong D.
    BJU Int; 2019 Sep 15; 124(3):401-407. PubMed ID: 31141284
    [Abstract] [Full Text] [Related]

  • 13. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy.
    Rauscher I, Düwel C, Haller B, Rischpler C, Heck MM, Gschwend JE, Schwaiger M, Maurer T, Eiber M.
    Eur Urol; 2018 May 15; 73(5):656-661. PubMed ID: 29358059
    [Abstract] [Full Text] [Related]

  • 14. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
    Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J.
    Lancet Oncol; 2019 Sep 15; 20(9):1286-1294. PubMed ID: 31375469
    [Abstract] [Full Text] [Related]

  • 15. How accurate is 68Gallium-prostate specific membrane antigen positron emission tomography / computed tomography (68Ga-PSMA PET/CT) on primary lymph node staging before radical prostatectomy in intermediate and high risk prostate cancer? A study of patient- and lymph node- based analyses.
    Erdem S, Simsek DH, Degirmenci E, Aydin R, Bagbudar S, Ozluk Y, Sanli Y, Sanli O, Ozcan F.
    Urol Oncol; 2022 Jan 15; 40(1):6.e1-6.e9. PubMed ID: 34400066
    [Abstract] [Full Text] [Related]

  • 16. Head-to-head comparisons of [68Ga]Ga-PSMA-11 PET/CT, multiparametric MRI, and prostate-specific antigen for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high-risk non-metastatic prostate cancer patients: a prospective study.
    Ke ZB, Chen SM, Chen JY, Chen SH, You Q, Sun JB, Xue YT, Sun XL, Wu XH, Zheng QS, Wei Y, Xue XY, Xu N.
    Eur J Nucl Med Mol Imaging; 2023 Mar 15; 50(4):1240-1251. PubMed ID: 36416906
    [Abstract] [Full Text] [Related]

  • 17. Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial.
    de Feria Cardet RE, Hofman MS, Segard T, Yim J, Williams S, Francis RJ, Frydenberg M, Lawrentschuk N, Murphy DG, De Abreu Lourenco R.
    Eur Urol; 2021 Mar 15; 79(3):413-418. PubMed ID: 33341285
    [Abstract] [Full Text] [Related]

  • 18. Prospective Evaluation of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography in Primary Prostate Cancer Diagnosis.
    Lopci E, Lughezzani G, Castello A, Saita A, Colombo P, Hurle R, Peschechera R, Benetti A, Zandegiacomo S, Pasini L, Casale P, Pietro D, Bevilacqua G, Balzarini L, Buffi NM, Guazzoni G, Lazzeri M.
    Eur Urol Focus; 2021 Jul 15; 7(4):764-771. PubMed ID: 32312701
    [Abstract] [Full Text] [Related]

  • 19. Comparison of digital and analog [68Ga]Ga-PSMA-11 PET/CT for detecting post-prostatectomy biochemical recurrence in prostate cancer patients: a prospective study.
    Kim YI, Lee DY, Sung C, Lee SJ, Oh SJ, Oh JS, Yoon S, Lee JL, Lim B, Suh J, Park J, You D, Jeong IG, Hong JH, Ahn H, Kim CS, Ryu JS.
    Sci Rep; 2024 Jul 01; 14(1):14989. PubMed ID: 38951530
    [Abstract] [Full Text] [Related]

  • 20. Detection efficacy of [89Zr]Zr-PSMA-617 PET/CT in [68Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer.
    Rosar F, Khreish F, Marlowe RJ, Schaefer-Schuler A, Burgard C, Maus S, Petto S, Bartholomä M, Ezziddin S.
    Eur J Nucl Med Mol Imaging; 2023 Jul 01; 50(9):2899-2909. PubMed ID: 37148297
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.